LGVN Longeveron Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1721484 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.9%
TTM net income YoY-4.9%
TTM EPS YoY134.5%
Revenue 3-yr CAGR15.0%
Net income 3-yr CAGR—
Margins
Gross margin66.4%
Operating margin-2,020.8%
Net margin-1,921.7%
FCF margin-1,560.1%
EBITDA margin-1,952.1%
Returns
ROE-305.1%
ROA-162.4%
ROIC (approx.)—
Asset turnover0.08x
Leverage & solvency
Liabilities / assets60.8%
Debt / equity0.00x
Current ratio1.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-31.8%
Payout ratio—
Capex / revenue14.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.20M | $2.39M | $709,000 | $1.22M | $1.31M |
| Cost of revenue | $396,000 | $508,000 | $488,000 | $725,000 | $716,000 |
| Gross profit | $803,000 | $1.88M | $221,000 | $497,000 | $590,000 |
| R&D expense | $12.04M | $8.14M | $9.07M | $9.37M | $7.09M |
| SG&A expense | $12.05M | $10.27M | $12.18M | $8.12M | $9.74M |
| Operating income | -$23.29M | -$16.52M | -$21.03M | -$18.04M | -$17.46M |
| Interest expense | — | — | — | $1.40M | $4,000 |
| Income tax | $0 | $0 | $0 | $0 | — |
| Net income | -$22.70M | -$15.97M | -$21.41M | -$18.84M | -$17.05M |
| EBITDA | -$22.49M | -$15.82M | -$20.33M | -$17.34M | -$17.46M |
| EPS (basic) | -1.29 | -2.62 | -10.22 | -0.90 | -0.90 |
| EPS (diluted) | -1.29 | -2.62 | -10.22 | -0.90 | -0.90 |
| Weighted avg. shares (diluted) | 17.58B | 9.41B | 2.17B | 20.97M | 18.92M |
| Balance sheet | |||||
| Cash & equivalents | $4.66M | $19.23M | $4.95M | $10.50M | $25.66M |
| Short-term investments | — | $0 | $412,000 | $9.15M | $9.47M |
| Receivables | $104,000 | $84,000 | $111,000 | $218,000 | $55,000 |
| Current assets | $5.45M | $19.62M | $5.85M | $20.28M | $35.38M |
| PP&E, net | $1.84M | $2.45M | $2.53M | $2.95M | $3.06M |
| Intangibles | $2.29M | $2.40M | $2.29M | $2.41M | $2.33M |
| Total assets | $10.26M | $25.56M | $12.08M | $27.41M | $42.77M |
| Current liabilities | $4.09M | $2.58M | $3.89M | $4.87M | $2.71M |
| Total liabilities | $4.59M | $3.67M | $5.34M | $6.91M | $5.31M |
| Shareholders' equity | $5.67M | $21.89M | $6.74M | $20.50M | $37.45M |
| Cash flow statement | |||||
| Operating cash flow | -$18.64M | -$13.87M | -$19.00M | -$13.97M | -$9.64M |
| Capital expenditure | $245,000 | $655,000 | $301,000 | $569,000 | $330,000 |
| Free cash flow | -$18.89M | -$14.52M | -$19.30M | -$14.54M | -$9.97M |
| Investing cash flow | -$595,000 | -$640,000 | $8.19M | -$677,000 | -$10.70M |
| Financing cash flow | $4.67M | $28.79M | $5.26M | -$509,000 | $45.17M |
| Depreciation & amortization | $800,000 | $700,000 | $700,000 | $700,000 | $1 |
| Stock-based compensation | $1.68M | $2.33M | $2.03M | $2.17M | $1.30M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.